USD 63.48
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CTLT | 0 | 0 | 0 | 5.3 | 9.7 | 28.5 | -38.9 | 3.3 | 126.1 | 217.6 |
| S&P 500 | -0.1 | 1.4 | 1.8 | 4.9 | 9.4 | 25.0 | 37.9 | 82.8 | 196.3 | 34330.7 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CTLT |
| name | Catalent, Inc. |
| price | 63.48 |
| changes percentage | 0 |
| change | 0 |
| day low | 63.44 |
| day high | 63.5 |
| year high | 63.5 |
| year low | 42.11 |
| market cap | 11522381760 |
| price avg 50 | 60.4114 |
| price avg 200 | 58.22005 |
| exchange | NYSE |
| volume | 13674041 |
| avg volume | 2268467 |
| open | 63.49 |
| previous close | 63.48 |
| eps | -2.28 |
| pe | -27.842105 |
| earnings announcement | 2025-02-07T13:30:00.000+0000 |
| shares outstanding | 181512000 |
| timestamp | 2024-12-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001596783 | |||
| revenue | 4381000000 | 4276000000 | 2.46 |
| gross profit | 953000000 | 1060000000 | -10.09 |
| gross profit ratio | 0.22 | 0.25 | -12.25 |
| research and development expenses | 0 | 18000000 | -100.00 |
| operating expenses | 1702000000 | 987000000 | 72.44 |
| interest income | 0 | 184000000 | -100.00 |
| interest expense | 254000000 | 184000000 | 38.04 |
| ebitda | -284000000 | 266000000 | -206.77 |
| ebitdaratio | -0.06 | 0.02 | -450.88 |
| operating income | -749000000 | -137000000 | -446.72 |
| operating income ratio | -0.17 | -0.03 | -433.61 |
| net income | -1043000000 | -232000000 | -349.57 |
| net income ratio | -0.24 | -0.05 | -338.79 |
| eps | -5.76 | -1.28 | -350.00 |
Revenue Growth: revenue increased to 4,381 million in 2024 from 4,276 million in 2023 representing a change of 2.46%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 1,702 million in 2024 from 987 million in 2023 representing a change of 72.44%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Operating Income: Operating income increased to -749 million in 2024 from -137 million in 2023 representing a change of -446.72%. The increase in operating income indicates better operational performance and increased profitability.
Gross Profit: Gross Profit decreased to 953 million in 2024 from 1,060 million in 2023 representing a change of -10.09%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 0 million in 2024 from 18 million in 2023 representing a change of -100.0%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -284 million in 2024 from 266 million in 2023 representing a change of -206.77%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -1,043 million in 2024 from -232 million in 2023 representing a change of -349.57%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -5.76 in 2024 from -5.76 in 2023 representing a change of -350.0%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001596783 | |||
| revenue | 1023000000 | 1301000000 | -21.37 |
| gross profit | 181000000 | 384000000 | -52.86 |
| gross profit ratio | 0.18 | 0.3 | -40.06 |
| research and development expenses | 0 | 5000000 | -100.00 |
| operating expenses | 252000000 | 224000000 | 12.50 |
| interest income | 0 | 0 | NaN |
| interest expense | 60000000 | 65000000 | -7.69 |
| ebitda | 56000000 | 290000000 | -80.69 |
| ebitdaratio | 0.05 | 0.22 | -75.44 |
| operating income | -71000000 | 160000000 | -144.38 |
| operating income ratio | -0.07 | 0.12 | -156.43 |
| net income | -129000000 | 23000000 | -660.87 |
| net income ratio | -0.13 | 0.02 | -813.29 |
| eps | -0.71 | 0.13 | -646.15 |
Revenue Growth: revenue decreased to 1,023 million in 2025Q1 from 1,301 million in 2024Q4 representing a change of -21.37%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 181 million in 2025Q1 from 384 million in 2024Q4 representing a change of -52.86%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 0 million in 2025Q1 from 5 million in 2024Q4 representing a change of -100.0%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 252 million in 2025Q1 from 224 million in 2024Q4 representing a change of 12.5%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to -71 million in 2025Q1 from 160 million in 2024Q4 representing a change of -144.38%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -129 million in 2025Q1 from 23 million in 2024Q4 representing a change of -660.87%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.71 in 2025Q1 from -0.71 in 2024Q4 representing a change of -646.15%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 56 million in 2025Q1 from 290 million in 2024Q4 representing a change of -80.69%. The increase in EBITDA indicates improved operational efficiency and profitability.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001596783 | |||
| total assets | 9753000000 | 10782000000 | -9.54 |
| total liabilities | 6149000000 | 6147000000 | 0.03 |
| total equity | 3604000000 | 4635000000 | -22.24 |
| cash and cash equivalents | 289000000 | 280000000 | 3.21 |
| short term investments | 109000000 | 0 | NaN |
| long term investments | 47000000 | -4074000000 | 101.15 |
| total current assets | 2597000000 | 2679000000 | -3.06 |
| total non current assets | 7156000000 | 8103000000 | -11.69 |
| total current liabilities | 1031000000 | 1507000000 | -31.59 |
| total non current liabilities | 5118000000 | 4640000000 | 10.30 |
| common stock | 2000000 | 2000000 | 0.00 |
| retained earnings | -781000000 | 262000000 | -398.09 |
| total debt | 4918000000 | 4849000000 | 1.42 |
Total Assets: Total Assets decreased to 9,753 million in 2024 from 10,782 million in 2023 representing a change of -9.54%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 6,149 million in 2024 from 6,147 million in 2023 representing a change of 0.03%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 3,604 million in 2024 from 4,635 million in 2023 representing a change of -22.24%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 2,597 million in 2024 from 2,679 million in 2023 representing a change of -3.06%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -781 million in 2024 from 262 million in 2023 representing a change of -398.09%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 4,918 million in 2024 from 4,849 million in 2023 representing a change of 1.42%. This indicates an increase in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 289 million in 2024 from 280 million in 2023 representing a change of 3.21%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 109 million in 2024 from 0 million in 2023 representing a change of nan%. This indicates an increase in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities decreased to 1,031 million in 2024 from 1,507 million in 2023 representing a change of -31.59%. This indicates a lower short-term debt burden.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001596783 | |||
| total assets | 9708000000 | 9753000000 | -0.46 |
| total liabilities | 6166000000 | 6149000000 | 0.28 |
| total equity | 3542000000 | 3604000000 | -1.72 |
| cash and cash equivalents | 335000000 | 289000000 | 15.92 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 156000000 | -100.00 |
| total current assets | 2507000000 | 2597000000 | -3.47 |
| total non current assets | 7201000000 | 7156000000 | 0.63 |
| total current liabilities | 998000000 | 1031000000 | -3.20 |
| total non current liabilities | 5168000000 | 5118000000 | 0.98 |
| common stock | 2000000 | 2000000 | 0.00 |
| retained earnings | -910000000 | -781000000 | -16.52 |
| total debt | 4947000000 | 4988000000 | -0.82 |
Total Assets: Total Assets decreased to 9,708 million in 2025Q1 from 9,753 million in 2024Q4 representing a change of -0.46%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 6,166 million in 2025Q1 from 6,149 million in 2024Q4 representing a change of 0.28%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 3,542 million in 2025Q1 from 3,604 million in 2024Q4 representing a change of -1.72%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 2,507 million in 2025Q1 from 2,597 million in 2024Q4 representing a change of -3.47%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -910 million in 2025Q1 from -781 million in 2024Q4 representing a change of -16.52%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 335 million in 2025Q1 from 289 million in 2024Q4 representing a change of 15.92%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 998 million in 2025Q1 from 1,031 million in 2024Q4 representing a change of -3.2%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 4,947 million in 2025Q1 from 4,988 million in 2024Q4 representing a change of -0.82%. This indicates a reduction in overall debt burden.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001596783 | |||
| net change in cash | 9000000 | -169000000 | 105.33 |
| operating cash flow | 268000000 | 261000000 | 2.68 |
| free cash flow | -59000000 | -322000000 | 81.68 |
| capital expenditure | -327000000 | -583000000 | 43.91 |
| depreciation and amortization | 489000000 | 422000000 | 15.88 |
| deferred income tax | -28000000 | -127000000 | 77.95 |
| stock based compensation | 68000000 | 35000000 | 94.29 |
| accounts payables | -84000000 | -21000000 | -300.00 |
| inventory | 109000000 | -192000000 | 156.77 |
| acquisitions net | 0 | -474000000 | 100.00 |
| investments in property plant and equipment | -327000000 | -583000000 | 43.91 |
| net cash used for investing activites | -327000000 | -962000000 | 66.01 |
| debt repayment | 84000000 | 485000000 | -82.68 |
| common stock issued | 9000000 | 4000000 | 125.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 74000000 | 521000000 | -85.80 |
| cash at end of period | 289000000 | 280000000 | 3.21 |
| accounts receivables | 79000000 | 53000000 | 49.06 |
| cash at beginning of period | 280000000 | 449000000 | -37.64 |
Net Change in Cash: Net Change in Cash increased to 9 million in 2024 from -169 million in 2023 representing a change of 105.33%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 268 million in 2024 from 261 million in 2023 representing a change of 2.68%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -59 million in 2024 from -322 million in 2023 representing a change of 81.68%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -327 million in 2024 from -583 million in 2023 representing a change of 43.91%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -28 million in 2024 from -127 million in 2023 representing a change of 77.95%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 68 million in 2024 from 35 million in 2023 representing a change of 94.29%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 84 million in 2024 from 21 million in 2023 representing a change of -300.0%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 79 in 2024 from 53 million in 2023 representing a change of 49.06%. This suggests that the company is less capable of collecting payments from its customers.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001596783 | |||
| operating cash flow | 61000000 | 214000000 | -71.50 |
| free cash flow | 4000000 | 139000000 | -97.12 |
| capital expenditure | -57000000 | -75000000 | 24.00 |
| depreciation and amortization | 113000000 | 130000000 | -13.08 |
| deferred income tax | -5000000 | -4000000 | -25.00 |
| stock based compensation | 17000000 | 16000000 | 6.25 |
| accounts receivables | 173000000 | -51000000 | 439.22 |
| accounts payables | -10000000 | -26000000 | 61.54 |
| inventory | -10000000 | 170000000 | -105.88 |
| acquisitions net | 23000000 | -1000000 | 2400.00 |
| investments in property plant and equipment | -57000000 | -75000000 | 24.00 |
| net cash used for investing activites | -34000000 | -74000000 | 54.05 |
| debt repayment | -5000000 | -5000000 | 0.00 |
| common stock issued | 1000000 | -9000000 | 111.11 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -10000000 | -10000000 | 0.00 |
| net change in cash | 46000000 | 127000000 | -63.78 |
| cash at end of period | 335000000 | 289000000 | 15.92 |
| cash at beginning of period | 289000000 | 162000000 | 78.40 |
Net Change in Cash: Net Change in Cash decreased to 46 million in 2025Q1 from 127 million in 2024Q4 representing a change of -63.78%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 61 million in 2025Q1 from 214 million in 2024Q4 representing a change of -71.5%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 4 million in 2025Q1 from 139 million in 2024Q4 representing a change of -97.12%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -57 million in 2025Q1 from -75 million in 2024Q4 representing a change of 24.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 17 million in 2025Q1 from 16 million in 2024Q4 representing a change of 6.25%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 173 in 2025Q1 from -51 million in 2024Q4 representing a change of 439.22%. This suggests that the company is less capable of collecting payments from its customers.
Accounts Payables: The absolute value of Accounts Payables decreased to 10 million in 2025Q1 from 26 million in 2024Q4 representing a change of 61.54%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q1 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-06-30 | 2023-06-30 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 24.2 | 23.62 | 2.46 |
| net income per share | -5.76 | -1.28 | -349.57 |
| operating cash flow per share | 1.48 | 1.44 | 2.68 |
| free cash flow per share | -0.33 | -1.78 | 81.68 |
| cash per share | 2.2 | 1.55 | 42.14 |
| book value per share | 19.91 | 25.61 | -22.24 |
| tangible book value per share | 2.38 | 3.4 | -30.19 |
| shareholders equity per share | 19.91 | 25.61 | -22.24 |
| interest debt per share | 28.5 | 27.81 | 2.50 |
| market cap | 10164960000 | 7848160000 | 29.52 |
| enterprise value | 14793960000 | 12417160000 | 19.14 |
| pe ratio | -9.75 | -33.83 | 71.19 |
| price to sales ratio | 2.32 | 1.84 | 26.42 |
| pocfratio | 37.93 | 30.07 | 26.14 |
| pfcf ratio | -172.29 | -24.37 | -606.87 |
| pb ratio | 2.82 | 1.69 | 66.57 |
| ptb ratio | 2.82 | 1.69 | 66.57 |
| ev to sales | 3.38 | 2.9 | 16.29 |
| enterprise value over ebitda | -52.09 | 46.68 | -211.59 |
| ev to operating cash flow | 55.2 | 47.58 | 16.03 |
| ev to free cash flow | -250.75 | -38.56 | -550.23 |
| earnings yield | -0.1 | -0.03 | -247.10 |
| free cash flow yield | -0.01 | -0.04 | 85.85 |
| debt to equity | 1.36 | 1.05 | 30.09 |
| debt to assets | 0.5 | 0.45 | 11.83 |
| net debt to ebitda | -16.3 | 17.18 | -194.89 |
| current ratio | 2.52 | 1.78 | 41.69 |
| interest coverage | -2.95 | -0.74 | -296.05 |
| income quality | -0.26 | -1.02 | 74.80 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0.0 | -100.00 |
| intangibles to total assets | 0.33 | 0.37 | -12.69 |
| capex to operating cash flow | 1.22 | 2.23 | -45.38 |
| capex to revenue | 0.07 | 0.14 | -45.26 |
| capex to depreciation | 0.67 | 1.38 | -51.60 |
| stock based compensation to revenue | 0.02 | 0.01 | 89.63 |
| graham number | 50.81 | 27.18 | 86.97 |
| roic | -0.09 | -0.01 | -740.25 |
| return on tangible assets | -0.16 | -0.03 | -362.14 |
| graham net net | -23.7 | -24.34 | 2.64 |
| working capital | 1566000000 | 1172000000 | 33.62 |
| tangible asset value | 430000000 | 616000000 | -30.19 |
| net current asset value | -3552000000 | -3468000000 | -2.42 |
| invested capital | 8460000000 | 8890000000 | -4.84 |
| average receivables | 1502500000 | 1468000000 | 2.35 |
| average payables | 392500000 | 422500000 | -7.10 |
| average inventory | 669000000 | 733000000 | -8.73 |
| days sales outstanding | 130.47 | 122.83 | 6.22 |
| days payables outstanding | 38.44 | 48.12 | -20.12 |
| days of inventory on hand | 61.12 | 86.71 | -29.52 |
| receivables turnover | 2.8 | 2.97 | -5.85 |
| payables turnover | 9.5 | 7.58 | 25.19 |
| inventory turnover | 5.97 | 4.21 | 41.88 |
| roe | -0.29 | -0.05 | -478.18 |
| capex per share | 1.81 | 3.22 | -43.91 |
ROE: Return on Equity (ROE) decreased to -0.29 on 2024-06-30 from -0.05 on 2023-06-30, representing a change of -478.18%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -9.75 on 2024-06-30 from -33.83 on 2023-06-30, representing a change of 71.19%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.52 on 2024-06-30 from 1.78 on 2023-06-30, representing a change of 41.69%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio:
| 2024-09-30 Q1 | 2024-06-30 Q4 | Q/Q change % | |
|---|---|---|---|
| CTLT | |||
| calendar year | 2025 | 2024 | NaN |
| revenue per share | 5.62 | 7.19 | -21.80 |
| net income per share | -0.71 | 0.13 | -657.79 |
| operating cash flow per share | 0.34 | 1.18 | -71.65 |
| free cash flow per share | 0.02 | 0.77 | -97.14 |
| cash per share | 1.84 | 1.6 | 15.28 |
| book value per share | 19.46 | 19.91 | -2.26 |
| tangible book value per share | 2.01 | 2.38 | -15.58 |
| shareholders equity per share | 19.46 | 19.91 | -2.26 |
| interest debt per share | 27.44 | 25.73 | 6.62 |
| market cap | 11023740000 | 10164960000 | 8.45 |
| enterprise value | 15635740000 | 14863960000 | 5.19 |
| pe ratio | -21.36 | 110.49 | -119.34 |
| price to sales ratio | 10.78 | 7.81 | 37.92 |
| pocfratio | 180.72 | 47.5 | 280.46 |
| pfcf ratio | 2755.93 | 73.13 | 3668.58 |
| pb ratio | 3.11 | 2.82 | 10.35 |
| ptb ratio | 3.11 | 2.82 | 10.35 |
| ev to sales | 15.28 | 11.43 | 33.78 |
| enterprise value over ebitda | 279.21 | 51.26 | 444.75 |
| ev to operating cash flow | 256.32 | 69.46 | 269.04 |
| ev to free cash flow | 3908.93 | 106.93 | 3555.43 |
| earnings yield | -0.01 | 0.0 | -617.18 |
| free cash flow yield | 0.0 | 0.01 | -97.35 |
| debt to equity | 1.39 | 1.27 | 9.30 |
| debt to assets | 0.51 | 0.47 | 7.92 |
| net debt to ebitda | 82.36 | 16.2 | 408.27 |
| current ratio | 2.51 | 2.52 | -0.27 |
| interest coverage | -1.18 | 2.46 | -148.07 |
| income quality | -0.47 | 9.3 | -105.08 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0.0 | -100.00 |
| intangibles to total assets | 0.33 | 0.33 | 0.56 |
| capex to operating cash flow | 0.93 | 0.35 | 166.62 |
| capex to revenue | 0.06 | 0.06 | -3.35 |
| capex to depreciation | 0.5 | 0.58 | -12.57 |
| stock based compensation to revenue | 0.02 | 0.01 | 35.12 |
| graham number | 17.62 | 7.55 | 133.49 |
| roic | -0.01 | 0.01 | -178.17 |
| return on tangible assets | -0.02 | 0.0 | -664.99 |
| graham net net | -24.51 | -24.3 | -0.86 |
| working capital | 1509000000 | 1566000000 | -3.64 |
| tangible asset value | 365000000 | 430000000 | -15.12 |
| net current asset value | -3659000000 | -3552000000 | -3.01 |
| invested capital | 8357000000 | 8460000000 | -1.22 |
| average receivables | 1512000000 | 1486000000 | 1.75 |
| average payables | 368000000 | 369000000 | -0.27 |
| average inventory | 563500000 | 672000000 | -16.15 |
| days sales outstanding | 128.27 | 108.33 | 18.40 |
| days payables outstanding | 40.08 | 35.43 | 13.13 |
| days of inventory on hand | 59.11 | 56.34 | 4.92 |
| receivables turnover | 0.7 | 0.83 | -15.54 |
| payables turnover | 2.25 | 2.54 | -11.61 |
| inventory turnover | 1.52 | 1.6 | -4.69 |
| roe | -0.04 | 0.01 | -670.69 |
| capex per share | 0.31 | 0.41 | -24.42 |
ROE: Return on Equity (ROE) decreased to -0.04 on 2024-09-30 Q1 from 0.01 on 2024-06-30 Q4, representing a change of -670.69%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -21.36 on 2024-09-30 Q1 from 110.49 on 2024-06-30 Q4, representing a change of -119.34%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.51 on 2024-09-30 Q1 from 2.52 on 2024-06-30 Q4, representing a change of -0.27%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio:
Negative Sentiment: Discounted Cash Flow value is -58.46 which is lower than current price 63.48, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 14:24:48
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Sentiment: Positive
Publish Date: 2024-12-18 17:46:00
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18.
Sentiment: Positive
Publish Date: 2024-12-18 09:08:43
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Sentiment: Positive
Publish Date: 2024-12-14 11:53:42
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Sentiment: Positive
Publish Date: 2024-12-14 00:08:00
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
Sentiment: Positive
Publish Date: 2024-12-14 00:06:00
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. “Today represents an important step in our t.
Sentiment: Positive
Publish Date: 2024-12-06 13:11:00
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
Sentiment: Positive
Publish Date: 2024-12-06 13:08:00
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. “We are pleased to have received European Commission approval, whic.
Sentiment: Positive
Publish Date: 2024-12-06 13:05:07
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Sentiment: Neutral
Publish Date: 2024-12-05 12:35:57
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Sentiment: Positive
Publish Date: 2024-11-22 12:37:40
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
Sentiment: Neutral
Publish Date: 2024-11-13 12:43:13
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
Sentiment: Positive
Publish Date: 2024-11-13 12:40:22
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Sentiment: Positive
Publish Date: 2024-11-06 10:11:01
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
Sentiment: Negative
Publish Date: 2024-11-05 09:25:21
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-05 08:25:33
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Sentiment: Positive
Publish Date: 2024-11-04 03:01:29
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
